Search Results
72 items found for "immune infiltration"
- 📰 GPCR Weekly News
Deletion of macrophage Gpr101 disrupts their phenotype and function dysregulating host immune responses
- Domain Therapeutics Raises $42m Series A Financing
"Published: May 10, 2022 To accelerate clinical development of its best-in-class and first-in-class immuno-oncology in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology
- Odorant receptors – a bit of smell for drug discovery
In the immune system ORs are expressed in different blood cells where aroma compounds from butter, known
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
Twice-daily treatment with mOB-004 dose-dependently suppressed monocyte infiltration into the peritoneum PROcisionXᵀᴹ discovery platform Structure-based validation of Orion’s approach Zheng, Y. et al. (2017) Immunity
- Glyco-sulfo hotspots in the chemokine receptor system
these PTMs in the chemokine receptor system which may ultimately allow for new precise targeting of the immune
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company
- 📰 GPCR Weekly News
Discovery Collaboration Domain Therapeutics strengthens Scientific Advisory Board with appointment of immuno-oncology
- 📰 GPCR Weekly News, April 17 to 23, 2023
Postdoctoral Researcher Director - Targeted Oncology Senior Scientist - Antibody Engineering Scientist—Immuno-Oncology
- 📰 GPCR Weekly News, May 1 to 7, 2023
Postdoctoral Researcher Director - Targeted Oncology Senior Scientist - Antibody Engineering Scientist—Immuno-Oncology
- 📰 GPCR Weekly News, July 17 to July 23, 2023
Domain Therapeutics announces the European Patent Office decision to grant a patent for its proprietary immuno-oncology
- 📰 GPCR Weekly News, October 16 to 22, 2023
manipulation, and potential use of Opn5 and its homologs Industry News The Leading GPCR Company in Immuno-Oncology
- 📰 GPCR Weekly News, May 8 to 14, 2023
Postdoctoral Researcher Director - Targeted Oncology Senior Scientist - Antibody Engineering Scientist—Immuno-Oncology
- 📰 GPCR Weekly News, April 10 to 16, 2023
GPCR Jobs NEW Director - Targeted Oncology NEW Senior Scientist - Antibody Engineering NEW Scientist—Immuno-Oncology
- 📰 GPCR Weekly News, January 1 to 7, 2024
strengthens leadership team to spearhead global development and North American expansion as the leading GPCR immuno-oncology
- 📰 GPCR Weekly News, April 24 to 30, 2023
Postdoctoral Researcher Director - Targeted Oncology Senior Scientist - Antibody Engineering Scientist—Immuno-Oncology
- 📰 GPCR Weekly News, March 25 to March 31, 2024
Therapeutics to Present Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology